Where does Kinnate Biopharma Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Kinnate Biopharma Inc. ranks #18,808 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Kinnate Biopharma Inc. hold?

Kinnate Biopharma Inc. holds 15 US utility patents granted between 2021 and 2024, spanning 4 technology areas.

What is Kinnate Biopharma Inc.'s Innovation Score?

Kinnate Biopharma Inc. has an Innovation Score of 50.6 out of 100 (top 13% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Kinnate Biopharma Inc. focus on?

Kinnate Biopharma Inc.'s top technology area is C07D (Heterocyclic Compounds) with 11 patents, ranking #741 of 3,165 assignees active in that subclass. Grants appear in 4 CPC subclasses total.

Is Kinnate Biopharma Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Kinnate Biopharma Inc..

What does claim depth mean for Kinnate Biopharma Inc.'s patents?

Kinnate Biopharma Inc.'s patents average 23.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Kinnate Biopharma Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Kinnate Biopharma Inc.

USPTO PatentsView assignee record - 15 granted patents across 4 technology areas, recorded in grant years 2021–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Kinnate ranks #18,808 of 49,997 tracked US assignees by granted-patent volume, with 15 patents across 4 technology areas.

#18,808
of 49,997 US assignees by volume: Top 13%
by Innovation Score (50.6/100): 23.2
avg claims per patent

USPTO PatentsView assignee plate

Corpus R18808 · US Corporation #18,808 · 15 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 15 grants
MID-PACK #18,808/49,997
PHOTO-FINISH K9 Sport Sack
CPC-NARROW C07D · 4 areas
INNOV-PAR 50.6/100
CLAIMS-DENSE 23.2 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2021–2024 · 4y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: K9 Sport Sack, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Kinnate’s 50.6 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 9.6 pts (19%) Velocity 20.0 pts (40%) Breadth 7.1 pts (14%) Claim depth 13.9 pts (27%)

Qualcomm Incorporated · highest

85
Kinnate Biopharma · this assignee

51
3D Lighting… · lowest

7

What this shows Kinnate's Innovation Score is 50.6/100 (top 13% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Kinnate?

Each dot is one of Kinnate’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Kinnate’s own 23.2 claims/patent is ABOVE the 12.9 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Kinnate vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Kinnate's grants concentrate

Kinnate Biopharma Inc. is a focused PatentsView assignee: 4 CPC subclasses with 73.3% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2022 (5 grants) versus a trough of 2 in 2024. By volume, Kinnate sits between K9 Sport Sack, LLC and Kuryakyn Holdings, LLC.

Kinnate's three-year grant acceleration

Kinnate Biopharma Inc. shows 12 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

K9 Sport Sack

15
KB Medical

15
King's Flair Deve…

15
Kinik

15
Klinikum Rechts D…

15
Kode Biotech

15
Kronoplus Technic…

15
Kuryakyn Holdings

15
Kinnate Biopharma ◀

15

What this shows Kinnate holds 15 patents at rank #18,799, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Kinnate

By rank, the assignees closest to #18,799 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Kinnate's primary technology class.

Kinnate's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

51 Top 13% higher than 87% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2021–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.

View data table

Kinnate Biopharma Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2021	3	20.0%
2022	5	33.3%
2023	5	33.3%
2024	2	13.3%

Which technologies does Kinnate Biopharma Inc. patent most?

C07D - Heterocyclic Compounds 11

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 6

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 3

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 2

Top 4 of 4 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Kinnate Biopharma Inc.'s patent record in context - here's where to go next.

Kinnate Biopharma Inc.'s lead technology class is C07D (Heterocyclic Compounds), 73.3% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #18,808 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Kinnate Biopharma Inc. against K9 Sport Sack, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 50.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.